Can we predict lung transplant outcomes? new study seeks answers
NCT ID NCT07356752
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows about 4,200 lung transplant recipients in France to understand why some people develop serious complications like chronic lung allograft dysfunction (CLAD). Researchers will collect routine health data, lung function tests, and blood samples to build a model that predicts how well a transplanted lung will work over time. The goal is to identify early warning signs so doctors can act sooner and personalize care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to better tools for doctors to predict and catch lung transplant problems early, potentially improving long-term survival.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly change patient care, and the prediction models might not work as well in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 4,200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2025
- Expected to finish
-
Jun 2031
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
15 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patients aged 15 and over transplanted (first or re transplantation, single, bilateral or combined) between 01/01/2009 and the date of the first prospective inclusion, benefiting from regular monitoring in one of the participating centers 2. Or Newly transplanted patient single, bilateral LTx, combined LTx) aged of 15 or more at the moment of transplantation, in one of the participating centers between the date of the first prospective inclusion during three years 3. Patients understanding the French language 4. Having signed an informed consent form for this study\*, and for patients aged 15 to 18 that the holder(s) of parental authority has signed the informed consent 5. Being covered by a national health insurance \* Already transplanted patient deceased before the beginning of the study: only clinical data (including biological samples clinically indicated likely to be reused, like serum of transbronchial biopsy (tbb)) will be included under condition of tracing any refusal, reluctance, reservations to the use of data, in patient files, by text analysis in all available digital documents. This approach allows both an exhaustive analysis in a timely, rapid way, that human reading would not allow. In case of mention of refusal, reluctance, reservations, the patient's data will not be collected. Exclusion Criteria: 1. Hemoglobin levels inferior than or equal to 8g/dl 2. Patients not understanding the French language 3. Don't being covered by a national health insurance 4. Being under guardianship or curatorship 5. Pregnant women\* \* Candidate for LTx are not allowed for pregnancy. During the follow up, pregnancies are permitted subject to medical approval of the project and close monitoring. It was decided that during pregnancy the participation for biocollection, would be suspended temporally. Realistically 1/ in the former situation patient candidate for Lung transplantation are not pregnant, 2/ in contrast long after transplantation, medically supervised pregnancy could occur. In that case, research sampling might be suspended temporarily.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic lung allograft dysfunction (CLAD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
APHP - site de Bichat
Paris, Paris 18, 75018, France
-
APHP - site de Cochin
Paris, Paris 14, 75014, France
-
CHU Bordeaux & INSERM U1045
Talence, Talence, 33404, France
-
CHU LYON
Lyon, 69007, France
-
CHU Nantes Hôpital Maison Blanche
Nantes, 44000, France
-
CHU Strasbourg
Strasbourg, Strasbourg, 67084, France
-
CML La Fondation Hôpital Saint-Joseph
Le Plessis-Robinson, 92350, France
-
Chu Grenoble
Grenoble, 38700, France
-
Hôpital Foch
Suresnes, 92150, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Magnetic pulses to the brain may help lung transplant patients sleep
- Rapid test may cut time on wrong antibiotics after lung transplant
- Can muscle strength predict lung transplant recovery?
- Blood markers may flag lung transplant danger — study investigates
- Your genes may hold the key to safer lung transplants
- Blood test clues could make antifungal dosing safer for transplant patients